Anavex Life Sciences Corp宣布,将根据监管机构的要求,提交其Anavex2-73-AD-004二期b/三期临床试验项目中现有的数据。该举措旨在推进相关审查流程。
Anavex Life Sciences Corp宣布,将根据监管机构的要求,提交其Anavex2-73-AD-004二期b/三期临床试验项目中现有的数据。该举措旨在推进相关审查流程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.